MedLine Search: Antineoplastons
Legacy MedLine Search
This MedLine Search of the technical medical literature is from the early days of CancerGuide so it may not include the latest research. The articles referenced are still relevant but more recent ones may also be available. For more information on the incredibly powerful and freely available MedLine database see my Article on Medline.
In all cases I have selected the references that looked most interesting to me. These are searches with a point of view! There could be references on this same subject that I didn’t include that you would have. For both of these reasons as well as the age of the search, you may want to consider doing your own search on this subject after looking at mine.
Finally, keep in mind that the abstracts presented here are only summaries of the actual articles. If you want to delve deeper you may want to get some of these articles from a Medical Library or an online document delivery service, as is provided with all MedLine accesses (usually for a fairly substantial fee).
Burzynski SR Stolzmann Z Szopa B Stolzmann E Kaltenberg OP Antineoplaston A in cancer therapy. (I). In: Physiol Chem Phys (1977) 9(6):485-500 Twenty-one patients with advanced cancer or leukemia were treated with antineoplaston A and followed for up to nine months. Dosage by intravenous, intramuscular, subcutaneous, rectal, intrapleural, intravesical and/or topical administration ranged from 0.6 to 33 U/m2/24 h. Treatment was well tolerated, although side effects included fever of short duration and elevation of platelet and white blood count. In 18 cases some degree of clinical improvement was observed. Complete remission occurred in 4 cases. More than 50% remission occurred in 4 other cases which, along with another 6 cases, are continuing the treatment with high doses of antineoplaston A and show a continuing regression of the tumors although not yet achieving the criteria for complete remission; 2 of these 6 cases seem unlikely to achieve remission. Two patients temporarily discontinued treatment. During treatment, 5 patients expired; in 2 of them, however, was seen significant regression of the neoplastic process. The deaths were not due to cancer or to any toxicity incurred by the treatment. Burzynski SR Stolzmann Z Szopa B Stolzmann E Kaltenberg OP ANTINEOPLASTON A IN CANCER THERAPY (I) In: Physiol Chem Phys (1977) 9(6):485-500 Antineoplaston A (ANA), a peptide from human urine, was given to 21 patients with far-advanced tumors who were followed for 1-9 mo. Most were resistant to chemotherapy and/or radiotherapy. ANA caused complete remissions (CR) in 2/2 patients with Grade III transitional cell carcinomas of the bladder, 1/6 with advanced breast cancer, and a child with acute lymphoblastic leukemia. ANA caused partial remissions (PR) in 2/3 patients with chronic lymphocytic leukemia (CLL), 1/2 with rectal adenocarcinoma, and a 20-yr-old man with lung metastases from synovial sarcoma. Six patients (1 each with breast cancer, rectal adenocarcinoma, undifferentiated ovarian tumor, squamous cell carcinoma of the tongue or cervix, and Ewing's sarcoma) showed stabilization of disease (SD). The patients with tongue cancer and Ewing's sarcoma relapsed within about 2 mo. All of the PR patients and 4/6 SD patients were continuing to improve at the time of report. It was hoped that the SD patients would reach a PR and the PR patients a CR. Five patients died during treatment, but not of cancer or toxicity; 2/5 showed significant tumor regression at autopsy. ANA caused marked central necrosis of solid tumors. Most patients showed a transient increase of WBC and platelet counts after about 1 mo of treatment. Some had a febrile syndrome, apparently caused by tumor cell breakdown. The recommended treatment is continuous iv infusion (1.2 units/m**2/day, gradually increased to 33 units/m**2 or the development of fever) for about 1 mo, followed by lower doses (0.6 units, 2x/wk) im or rectally. ANA caused no significant toxicity at the doses used (0.6-33 units/m**2/day, iv, im, rectally, intrapleurally, intravesically, or topically). (14 Refs) American Cancer Society UNPROVEN METHODS OF CANCER MANAGEMENT: ANTINEOPLASTONS In: CA Cancer J Clin (1983) 33(1):57-59 Use of antineoplastons as an alleged anticancer treatment is discussed. Antineoplastons are described as two specific chemical fractions extracted and purified from human urinary peptides and acclaimed to inhibit growth of cancer cells in tissue culture. Only one study details its clinical use in 21 patients; the drug has not been approved by the Food and Drug Administration and no evidence has been submitted that it is a safe and effective method for cancer therapy. (10 Refs) Burzynski SR Kubove E Burzynski B Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. In: Drugs Exp Clin Res (1990) 16(7):361-9 Successful treatment of advanced cancer of the prostate which no longer responds to hormonal manipulation continues to be a difficult task. The present study describes the results of treatment of the first fourteen patients in Phase II clinical trials with Antineoplaston AS2-1 (AS) and low-dose diethylstilbestrol (DES). The study involved thirteen patients diagnosed with stage IV and one patient with stage II adenocarcinoma of the prostate. The ages of the patients were between 54 and 88. The previous therapy included prostatectomy, orchiectomy, radiation therapy and treatment with DES, LHRH agonist (LH), flutamide (FL), aminoglutethimide and immunotherapy. After initial response to such treatments, the disease continued to progress. The majority of patients showed progression of the disease after treatment with LH and FL. The current treatment program consisted of administration of AS and DES. The treatment was given orally daily. The majority of patients received from 97 to 130 mg/kg/24 h of AS and from 0.01 to 0.02 mg/kg/24 h of DES. The treatment was administered from 64 to 425 days and was free from significant side effects due to AS. The dose of DES was lower than usual, and only some patients experienced mild side effects typical for DES. Only two patients showed progression of the disease. Complete remission was obtained in two patients and partial remission in three patients. Stabilization of the disease with objective improvement was determined in seven patients. The first patient enrolled in the program has been in complete remission for 17 months and off the treatment for 16 months.(ABSTRACT TRUNCATED AT 250 WORDS) Burzynski SR Kubove E Burzynski B Phase I clinical studies of antineoplaston A5 injections. In: Drugs Exp Clin Res (1987) 13 Suppl 1:37-43 Antineoplaston A5 is a mixture of small peptides and amino acid derivatives isolated from human urine which show a unique pattern of growth inhibition in the tissue culture of human neoplastic cells and no significant animal toxicity. Clinical trials described in this paper involved 15 patients diagnosed with advanced neoplastic diseases. The patients' diagnoses included: lung cancer, stage III (4 cases); breast, stages III and IV (3); colorectal, stage IV (2); bladder (2); and single cases of adenocarcinoma of the jejunum, stage IV; adenocarcinoma of the prostate, stage IV; adenocarcinoma of the ovary, stage IV and astrocytoma, grade IV. Antineoplaston A5 was administered daily in divided doses intravenously through a subclavian vein catheter. The formulation was given from 47 to 130 days. The highest dosage attained was 153 mg/kg/24 h. Adverse effects included febrile reaction in five patients, arthralgia in one patient and premature beats and pressure in the chest in one patient. The side-effects were very mild and usually experienced only once during the entire course of treatment. Desirable side-effects included increase of platelet count, increase of white blood cell count and hypertrophy of epidermis. Nine patients (60%) had objective response to the treatment. They were diagnosed with cancer of the lung (3 patients), breast (2), colorectal (2) and bladder (2). Four patients had increasing disease and two patients were classified as having stable disease without objective improvement. Burzynski SR Kubove E Phase I clinical studies of antineoplaston A3 injections. In: Drugs Exp Clin Res (1987) 13 Suppl 1:17-29 Antineoplaston A3 is an oxidated mixture of small peptides and amino acid derivatives isolated from human urine which have shown antineoplastic activity in tissue culture and low toxicity in mice. Twenty-four patients diagnosed with 25 cases of neoplastic diseases were involved in the studies. The patients' diagnoses included: adenocarcinoma of the prostate, stage IV (7 cases); adenocarcinoma of the breast, stage IV (3); adenocarcinoma of the colon and rectum, stage IV (3); adenocarcinoma of the colon, status post resection (1); adenocarcinoma of the lung, stage III (2); squamous cell carcinoma of the lung, stage III (2); adenocarcinoma of the pancreas, stages II and IV (2); and single cases of adenocarcinoma of the kidney, stage IV; malignant fibrohistiocytoma, stage IV; glioblastoma multiforme, stage IV; basal cell epithelioma; and transitional cell carcinoma of the bladder, grade II. Only patients who had over six weeks' anticipated survival and who continued the treatment for over six weeks were eligible. In 23 patients, Antineoplaston A3 was administered in divided doses daily i.v. through a subclavian vein catheter. In one patient, the injections were given i.m. The length of treatment was from 44 to 478 days and the highest dosage was 76 mg/kg/24 h. Side-effects associated with treatment included febrile reaction (4 patients), vertigo (2), headache (2), flushing of the face, nausea and tachycardia (1 each). Adverse reactions were mild and occurred only once during the entire course of treatment. Desirable side-effects included increase of platelet count, increase of white blood cell count and increase of reticulocyte count. At the end of the study, there were 5 cases of complete remission, 5 of partial remission, nine of stable disease and six of increasing disease. The patients who obtained complete remission were diagnosed with cancers of the bladder, prostate, colon, and basal cell epithelioma. In view of its very limited toxicity and the interesting responses obtained, Antineoplaston A3 was submitted for Phase II clinical trials to establish its usefulness in cancer treatment. Burzynski SR Kubove E Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. In: Drugs Exp Clin Res (1987) 13 Suppl 1:1-11 This paper describes Phase I clinical studies of Antineoplaston A2 injections. The studies involved 15 patients diagnosed with advanced neoplastic diseases including cancers of the breast, bladder, lung, kidney, oesophagus, colon and liver, mesothelioma and glioma. Antineoplaston A2 was administered in divided doses daily intravenously through a subclavian vein catheter. The treatment was given from 53 to 358 days. The highest dosage administered was 147 mg/kg/24 h. Only minimal adverse effects were noticed sometime during the treatment, including fever, chills and myalgia. Desirable side- effects included increase of platelet and white blood cell counts, hypertrophy of epidermis and decrease of cholesterol and triglyceride levels. Nine patients showed objective response to the treatment. Cases of complete remission included adenocarcinoma of the lung, mesothelioma, metastatic liver and bladder cancers. In an additional case of breast cancer, the patient obtained complete remission of liver metastasis and stabilization of bone metastases. Partial remission was accomplished in cancers of the breast and oesophagus. Three patients, including cases of adenocarcinoma of the lung, mesothelioma and bladder cancer, were in complete remission for over five years. Burzynski SR Kubove E Toxicology studies on antineoplaston A10 injections in cancer patients. In: Drugs Exp Clin Res (1986) 12 Suppl 1:47-55 Antineoplaston A10 injections were administered to 18 patients diagnosed with 19 types of neoplastic disease. The patients' diagnoses included: adenocarcinoma of the rectum and colon, Stage IV (8 cases); adenocarcinoma of the pancreas (4 cases); adenocarcinoma of the breast, Stage IV (3 cases) and single cases of adenocarcinoma of the lungs, Stage III; adenocarcinoma of the stomach, Stage IV; chondrosarcoma of the nose and right maxillary sinus; and carcinoid. The treatment was administered from 52 to 640 days. The highest dosage taken was 2210.5 mg/kg/24 h. Most of the patients were taking from 206.9 to 387.1 mg/kg/24 h. The treatment was associated with minimal side-effects including febrile reactions, muscle and joint pain, muscle contraction in the throat, abdominal pain of short duration and single incidences of nausea, dizziness and headache. Desirable side-effects included increase of platelet count and white blood cell count. Objective response to the treatment was noticed in 8 patients including one patient diagnosed with intraductal carcinoma of the breast, Stage IV, 2 patients with adenocarcinoma of the sigmoid, Stage IV, 1 patient with adenocarcinoma of the rectum, Stage IV, 2 patients with adenocarcinoma of the pancreas, 1 patient with adenocarcinoma of the lung, Stage III, and 1 chondrosarcoma. Burzynski SR Burzynski B Mohabbat MO Toxicology studies on antineoplaston AS2-1 injections in cancer patients. In: Drugs Exp Clin Res (1986) 12 Suppl 1:25-35 Antineoplaston AS2-1 is a mixture of two products of hydrolysis of Antineoplaston A10 and consists of sodium salts of phenylacetylglutamine and phenylacetic acid in the ratio of 1:4. Antineoplaston AS2-1 injections were administered to 20 patients diagnosed with 21 types of neoplastic diseases. The patients' diagnoses included: lung cancer, stage III, 4 cases; colorectal, stage IV, 3; breast, stage IV, 2; breast in remission, 1; glioblastoma, 3; head and neck, stage IV, 3; uterine cervix, stage IA, 1; chronic myelocytic leukaemia, 2; lymphocytic lymphoma, stage IV, 1; and leiomyosarcoma of the uterus, stage IVB, 1. Antineoplaston AS2-1 was administered every 6 h i.v. through subclavian vein catheter. The treatment was administered from 38 to 872 days. The highest dosage taken was 160 mg/kg/24 h. The treatment was associated with minimal side-effects, including slight nausea and vomiting in one patient, mild allergic reaction in the form of maculopapular rash in another patient and moderate elevation of blood pressure in an additional patient. One patient developed febrile reaction and three patients had mild electrolyte imbalance. Only one patient showed slight decrease of WBC. Desirable side-effects included improved healing of chronic atrophic ulceration. The response to the treatment included 6 complete remissions, 2 partial remissions, 7 cases of stabilization and 6 cases of increasing disease. Three patients are alive, well and free from cancer 5 years after the beginning of the study. The hypothetical mechanism of action of Antineoplaston AS2-1 as an anticancer agent is described. Burzynski SR Toxicology studies on antineoplaston AS2-5 injections in cancer patients. In: Drugs Exp Clin Res (1986) 12 Suppl 1:17-24 Antineoplaston AS2-5 is one of the degradation products of Antineoplaston A10. The chemical structure of Antineoplaston AS2-5 corresponds to phenylacetylglutamine. Toxicology studies of Antineoplaston AS2-5 injections involved 13 patients diagnosed with 15 types of neoplastic disease, including: lung cancer, 3 cases; breast, 3 cases; colon, 2 cases; and single cases of cancer of the larynx, prostate, stomach, pancreas, malignant fibrohistiocytoma, embryonal teratoma and lymphocytic lymphoma. Antineoplaston AS2-5 was injected i.v. daily through subclavian vein catheter in divided doses. The treatment was administered from 41 to 436 days. The highest dosage given was 167.6 mg/kg/24 h. The treatment was associated with only very mild side-effects, including febrile reaction in two patients and swelling of small joints in one patient. Two patients had beneficial side-effects, including increase of platelet count and increase of concentration of plasma globulin. The treatment resulted in two complete remissions, one mixed response, four cases of stabilization and six cases of increasing disease. Complete remission was achieved in squamous cell carcinoma of the larynx, stage II, and large cell undifferentiated carcinoma of the lung with lymph nodes and liver metastases. One patient had mixed response during the treatment of carcinoma of the breast with metastases to the lymph nodes, liver and skin and obtained complete remission of liver metastases but increasing disease of skin metastases. Eight patients discontinued the treatment and three patients died during the trials. The patient diagnosed with lung cancer who obtained complete remission continues to be free from the disease over 5 years after the beginning of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS) Burzynski SR Mohabbat MO Burzynski B TOXICOLOGY STUDIES ON ORAL FORMULATION OF ANTINEOPLASTON A10 IN CANCER PATIENTS In: Future Trends Chemother (1985) 6:485-93 Antineoplaston A10 (AN A10; 3-phenylacetylamino-2,6-piperidinedione)-- the first compound belonging to the group of antineoplastons to be identified and reproduced by synthesis--tested in animals did not show any significant toxic effects and has LD50 equal to 10.33 g/kg. Chronic administration of AN A10, 500-mg capsules, is described for 42 patients diagnosed with 49 types of advanced neoplastic disease: breast cancer (13 cases); prostate (7); lung (7); colorectal (4); kidney (2); bladder (2); single cases of cancer of the stomach, pancreas, cervix, ovary, and parotid gland; 3 cases of primary malignant brain tumor; 5 leukemias and lymphocytic lymphomas, and 1 unknown tissue diagnosis. The shortest duration of treatment was 6 days and the longest 314 days; most of the patients were treated for 50-149 days. The highest dose of AN A10 per 24 hr was 14.0 g; the highest dosage of AN A10 taken was 288.4 mg/kg/24 hr. Results are presented for (1) adverse reactions (cardiovascular, febrile reaction, gastrointestinal symptoms, hypersensitivity, hypoglycemia, hypokalemia, myelosuppression, neurological effects) and (2) cancer treatment (complete or partial remission, stable disease, increasing disease, withdrawal from treatment, additional beneficial effects from treatment). Treatment was associated with minimal adverse reactions which included excess gas in the stomach, gastrointestinal bleeding (probably not related to AN A10), maculopapular rash, moderately increased blood pressure, vertigo, hypoglycemia, hypokalemia, and mild myelosuppression. Evaluation of anticancer activity was not the main purpose of the study; however, at least some positive response reflected by clinical improvement was found in 75% of the 49 cases studied. In the majority of cases (51%), the positive response was limited to stabilization. Additional beneficial effects of treatment with AN A10 included decrease of plasma levels of triglycerides and cholesterol, increase in white blood count, red blood count and platelet count, and the improvement of blood clotting. (8 Refs) Burzynski SR Kubove E Szymkowski B Burzynski B Phase II clinical trials of novel differentiation inducer-- antineoplaston AS2-1 in AIDS and asymptomatic HIV infection. In: Int Conf AIDS (1992 Jul 19-24) 8(3):61 (abstract no. PuB 7074) OBJECTIVES: Demonstration of objective improvement in AIDS and asymptomatic HIV infection (AHIV) in response to treatment with Antineoplaston AS2-1 (AS). METHODS: Seventy evaluable patients included in the studies were divided into 3 groups: AHIV, AIDS not previously treated, and AIDS resistant to antiviral therapy (AIDSR). AHIV patients were given the average oral dosage of 50mg/kg/24h, and AIDS and AIDSR 35mg/kg/24h. The responses were evaluated using generally accepted criteria with special emphasis on CD4+ counts. The patients in the AHIV group had pretreatment CD4+ counts below 500/mm3, and the majority in the AIDSR group had CD4+ counts from 0 to 40/mm3. The duration of the studies was 180 days. RESULTS: The evaluation after 60 to 90 days revealed response rates of 68% for AHIV, 81% for AIDS and 61% for AIDSR. After 180 days of treatment, the response rates decreased to 64% for AHIV, 44% for AIDS and 28% for AIDSR. A number of patients discontinued the treatment during the first 6 months for nonmedical reasons. At the time of this report only a small number of patients, who decided to continue therapy over 180 days, completed 10 to 12 months of treatment. The majority of these patients continue to show objective improvement. There were no significant side effects associated with the treatment. Responding patients had marked increase of CD4+ count. The highest net increase of CD4+ counts were 450/mm3 (AIDSR), 430/mm3 (AHIV), and 220/mm3 (AIDS). There was marked clinical improvement, including increases of energy and weight, and a decrease of opportunistic infections. CONCLUSION: It is concluded that (AS) shows therapeutic activity in the treatment of AHIV, AIDS and AIDSR. Additional study will be required to determine the response rate in a large number of patients. Tsuda H Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. The members of Antineoplaston Study Group. In: Kurume Med J (1990) 37(2):97-104 The inhibitory effect of Antineoplaston A-10 was tested on the growth curve of human breast cancer (R-27) serially transplanted to athymic mice and on the cell growth of human hepatocellular carcinomas (KMCH- 1, KYN-1, KIM-1). Approximately 1.25% of Antineoplaston A-10 in the regular mouse diet (CE2) inhibited the growth curve significantly after 35 days treatment (p less than 0.05). Seventy milligrams of daily intraperitoneal administration of Antineoplaston A-10 Injection also inhibited the growth curve of R-27 after 52 days treatment (p less than 0.01). Histological study of tumor showed no essential difference in structure but significant decrease in number of mitoses in the Antineoplaston A-10 treated groups. The cell growth of human hepatocellular carcinoma cell lines KMCH-1, KYN-1 and KIM-1 was inhibited by Antineoplaston A-10 Injection dose dependently. Institutional address: Kurume University School of Medicine Japan. Hashimoto K Koga T Shintomi Y Tanaka M Kakegawa T Tsuda H Hara H The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice. In: Nippon Gan Chiryo Gakkai Shi (1990 Jan 20) 25(1):1-5 We report the effects of Antineoplaston A-10 Injection on the growth curve of human breast cancer (R-27) serially transplanted to athymic mice. The intraperitoneal administration of 1/4 LD-50 (50 mg/mouse) of Antineoplaston A-10 Injection every day and 1/2 LD-50 (100 mg/mouse) every other day for 35 days was found to significantly inhibit the growth curve and also the 3H-TdR uptake was inhibited by 73.7% in those given 1/4 LD-50 and by 77.1% in those given 1/2 LD-50. The tumor histology in both groups showed necrosis but no lymphocyte infiltration.